A patient with adrenocortical carcinoma: Characterization of its biological activity and drug resistance profile

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 389-394

  Feller, Nicole ^b   Hoekman, Klaas ^b   Kuiper, Catharina M ^b   Linn, Sabine C ^b   Verheul, Hendrick M W ^b   Wolthers, Bert G ^a   Popp Snijders, Corrie ^b   Pinedo, Herbert M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOTANE; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; ADULT; APOPTOSIS; ARTICLE; CASE REPORT; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; STEROID URINE LEVEL;

ADRENAL CORTEX NEOPLASMS; ADULT; ANDROGENS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GENES, P53; GLUCOCORTICOIDS; HUMANS; MALE; MINERALOCORTICOIDS; MITOTANE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES; VINCRISTINE;

EID: 0030887352     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Freeman, D. A. Steroid hormone-producing tumors in man. Endocr. Rev., 7: 204-220, 1986.
2. Samaan, N. A., and Mickey, R. C. Adrenal cortical carcinoma. Semin. Oncol., 14: 292-296, 1987.
3. Icard, P., Chapuis, Y., Andreassian, B., Bernard, A., and Proye, C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery, 112: 972-980, 1992.
4. Scott, H. W., Sussman, C. R., Page, D. L, Thompson, N. W., Gross, M. D., and Lloyd, R. Primary hyperaldosteronism caused by adrenocortical carcinoma. World J. Surg., 10: 646-653, 1986.
5. Arteaga, E., Biglieri, E. G., Kater, C. E., Lopez, J. M., and Schambelan, M. Aldosterone-producing adrenocortical carcinoma. Ann. Intern. Med., 101: 316-321, 1984.
6. Luton, J. P., Gerdas, S., Billaud, L., Thomas, G., Guilhame, B., Bertagna, X., Laudat, M. H., Louvel, A., Chapuis, Y., and Blondeau, P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med., 322: 1195-1201, 1990.
7. Jarabak, J., and Rice, K. Metastatic adrenal cortical carcinoma, prolonged regression with mitotane therapy. J. Am. Med. Assoc., 246: 1702-1707, 1981.
8. Vassilopoulou-Sellin, R., Guinee, V. F., Klein, M. J., Taylor, S. H., Hess, K. R., Schultz, P. N., and Samaan, N. A. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer (Phila.), 71: 3119-3123, 1993.
9. van Slooten, H., and van Oosterom, A. T. CAP (cyclophosphamide, doxorubicin and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat. Rep., 67: 377-379, 1983.
10. Schlumberger, M., Ostronoff, M., Bellaiche, M., Rougier, P. H., Droz, J. P., and Parmentier, C. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer (Phila.), 61: 1492-1494, 1988.
11. Flynn, S. D., Murren, J. R., Kirby, W. M., Honig, J., Kan, L., and Kinder, B. K. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery, 112: 981-986, 1992.
12. Bradley, G., Juranka, P. F., and Ling, V. Mechanism of multidrug resistance. Biochim. Biophys. Acta, 948: 87-128, 1988.
13. Broxterman, H. J., and Pinedo, H. M. Energy metabolism in multidrug resistant tumor cells: a review. J. Cell. Pharmacol., 2: 239-247, 1991.
14. Endicott, J. A., and Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 55: 137-171, 1989.
15. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., MacKie, J. E., Grant, C. E., Almquist K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
16. Scheffer, G. L., Wijngaard, P. L. J., Flens, M. J., Izquierda, M. A., Slovak, M. L., Pinedo, H. M., Meyer, C. J., Clevers, H. C., and Scheper, R. J. The drug resistance associated protein LRP is a major vault protein. Nat. Med., 1: 578-582, 1995.
17. Hickman, J. A. Apoptosis induced by anticancer agents. Cancer Metastasis Rev., 11: 121-139, 1992,
18. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog bax that accelerates programmed cell death. Cell, 74: 609-619, 1993.
19. Broxterman H. J., Feller, N., Kuiper, C. M., Boven, E., Versantvoort C. H. M., Teerlink, T., Pinedo, H. M., and Lankelma. J. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Int. J. Cancer. 61: 880-886, 1995.
20. van Slooten, H., Moolenaar, A. J., van Seters, A. P., and Smeenk, D. The treatment of adrenocortical carcinoma with o.p.-DDD; prognostic implications of serum level monitoring. Eur. J. Cancer Clin. Oncol., 20: 47-53, 1984.
21. Bates, S. E., Shieh, C., Mickley, L. A., Dichek, H. L., Gazdar, A., Loriaux, O. L., and Fojo, A. T. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J. Clin. Endocrinol. Metab., 40: 18-29, 1989.
22. Homoki, J., Holl, R., and Teller, W. M. Harnsteroid profile bei Cushing syndrom und tumoren der Nebennierenrinde. Klin. Wochenschr., 65: 719-726, 1987.
23. Gazdar, A. F., Oie, H. K., Shackleton, C. H., Chen, T. R., Triche, T. J., Myers, C. E., Chrousos, G. P., Brennan, M. F., Stein, C. A., and La Rocca, R. V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res., 50: 5488-5496, 1990.
24. Zijlstra, J. G., de Vries, E. G. E., and Mulder, N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47: 1780-1784, 1987.
25. Feller, N., Kuiper, C. M., Lankelma, J., Ruhdal, J. K., Scheper, R., Pinedo, H. M., and Broxterman, H. J. Functional detection of MDRI P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br. J. Cancer, 72: 543-549, 1995.
26. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Schroeijers, A. B., van der Valk, P., and Scheper, R. J. Broad distribution of the multidrug-resistance related vault protein LRP in normal human tissues and tumors. Eur. J. Cancer, 32A(6): 979-984, 1996.
27. Feller, N., Broxterman, H. J., Währe, D. C. R., and Pinedo, H. M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett., 368: 385-388, 1995.
28. Mossman, T. Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxic assays. J. Immunol. Methods, 65: 55-63, 1983.
29. Wolthers, B. G., de Vries, I. J., Volmer, M., and Nagel, G. T. Detection of 3β-hydroxysteroid dehydrogenase deficiency in a newborn by means of urinary steroid analysis. Clin. Chim. Acta, 169: 109-116, 1987.
30. Koopman, B. J., Lokerse, Y. G., Verweij, H., Nagel, G. T., van der Molen, J. C., Drayer, N. M., and Wolthers, B. G. Improved gas chromatographic-mass spectrometric assay for tetrahydroaldosterone and aldosterone in urine. J. Chromatogr. Biomed. Appl., 378: 283-292, 1986.
31. Kaspers, G. J. L., Pieters, R., Twentyman, P. R., Weisenthal, L. M., and Veerman, A. J. P. (eds.), Drug Resistance in Leukemia and Lymphoma: The Clinical Value of Laboratory Studies, pp. 345-352. Newark, NJ: Harwood Academic Publishers, 1993.
32. Muller, C, Chatelut, E., Gualano, V., De Forni, M., Huguet, F., Attal, M., Canal, P., and Laurent, G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol., 32: 379-384, 1993.
33. Rahmani, R., and Zhou, X. J. Pharmacokinetics and metabolism of Vinca alkaloids. Cancer Surv., 17: 269-281, 1993.
34. McLeod, H. L., and Evans, W. E. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv., 17: 253-268, 1993.
35. Danese, R. D., and Aron, D. C. Cushing's syndrome and hypertension. Endocrinol. Metab. Clin. North Am., 23: 299-324, 1994.
36. Saruta, T., Suzuki, H., Handa, M., Igarashi, Y., Kondo, K., and Senba, S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J. Clin. Endocrinol. Metab., 62: 275-279, 1986.
37. van Kalken, C. K., Broxterman, H. J., Pinedo, H. M., Feller, N., Dekker, H., Lankelma, J., and Giaccone, G. Cortisol is transported by the multidrug resistance product P-glycoprotein. Br. J. Cancer, 67: 284-289, 1994.
38. van der Valk, P., van Kalken, C. K., Ketelaars, H., Broxterman, H. J., Scheffer, G., Kuiper, C. M., Tsuruo, T., Lankelma, J., Meyer, C. J., and Pinedo, H. M. Distribution of multidrug resistance associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol., 1: 56-64, 1990.
39. Flens, M. J., Zaman, G. J. R., van der Valk, P., Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der Groep, P., de Haas, M., Meyer, C. J., and Scheper, R. J. Tissue distribution of the multidrug resistance associated protein (MRP). Am. J. Pathol., 148(4): 1237-1247, 1996.
40. Izquierdo, M. A., van der Zee, A. G. J., Vermorken, J. B., van der Valk, P., Belien, J. A., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., Meyer, C. J., de Vries, E. G. E., and Scheper, R, J. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87: 1230-1237, 1995.
41. List, A. F., Spier, C. S., Grogan, T. M., Johnson, C., Roc, D. J., Greer, J. P., Wolff, S. N., Broxterman, H. J., Scheffer, G. L., Scheper, R. J., and Dalton, W. S. Overexpression of the major vault transporter protein LRP predicts treatment outcome in AML. Blood, 87: 2464-2469, 1996.
42. Watson, A. J., Merritt, A. J., Jones, L. S., Askew, J. N., Anderson, E., Becciolini, A., Balzi, M., Potten, C, S., and Hickman, J. A. Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br. J. Cancer, 73(8): 889-895, 1996.
43. Haldar, S., Nigrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 in breast cancer cells. Cancer Res., 54(8): 2095-2097, 1994.